Fulvestrant Injection, Solution
Product Images NDC 63323-715

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 63323-715). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ful04 0006 01

FDA Label Image

Ful04 0006 02

FDA Label Image

Ful04 0006 03

FDA Label Image

Ful04 0006 04

FDA Label Image

Ful04 0006 05

FDA Label Image

Ful04 0006 06

This appears to be a graph showing the progression-free survival rate of two doses of Fulvestrant (250mg and 500mg) over a period of 45 months. The x-axis represents the time in months and the y-axis represents the number of patients who remained free from disease progression. The number of patients at risk for each dose is listed at each time point.*

FDA Label Image

Ful04 0006 07

The provided text contains a graph showing over time the number of patients still alive while receiving different doses of a drug called Fulvestrant. The graph shows that patients who received the 500mg dose had a lower survival rate over time compared to patients receiving the lower 250mg dose. The last statement suggests that the data may not be statistically significant without adjustments.*

FDA Label Image

Ful04 0006 08

FDA Label Image

Ful04 0006 09

This is a graph depicting the progression-free survival of two treatments for breast cancer: Palbociclib+fulvestrant versus placebo+fulvestrant. Palbociclib+fulvestrant shows greater efficacy in reducing cancer progression as compared to placebo+fulvestrant. The graph also shows the number of patients at risk for each treatment over the course of time.*

FDA Label Image

Ful04 0006 10

This is a chart that compares two treatment options for an unspecified medical condition. These options are fulvestrant with a placebo and a combination of fulvestrant and palbociclib. The chart shows the overall survival probability in percentage for patients over a period of 54 months. The number of patients at risk for the two options is also indicated at different time points.*

FDA Label Image

Ful04 0006 11

FDA Label Image

Ful04 0006 12

FDA Label Image

Ful04 0006 13

FDA Label Image

Ful04 0006 14

Not available.*

FDA Label Image

Ful04 0006 15

FDA Label Image

Ful04 0006 16

FDA Label Image

Ful04 0006 17

This is a description of Fulvestrant Injection, which is for single-dose intramuscular use only. It comes in a carton that contains two pre-filled syringes each containing 250 mg per 5 mL (50 mg per mL) and two SafetyGlide™ shielding intramuscular injection needles. Both syringes must be administered to receive the 500 mg dose. It can be stored at controlled room temperature or refrigerated conditions, but should not be frozen. It is important to protect from light, and store in the original carton until use. The manufacturer is Fresenius Kabi and it is available via prescription only.*

FDA Label Image

Ful04 0006 18

This is a description of a medication called Fulvestrant. It comes in an injection form, with a strength of 250mg per 5mL (50mg per mL). It is intended for intramuscular use only and should be administered using a bath syringe. A single-dose syringe with a code of 63323-715-01 is also available. This medication should only be prescribed by a doctor. Other details include a manufacturer address in Lake Zurich, IL and a reference to a code MOG1225/00 US 403319.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.